262 related articles for article (PubMed ID: 34917497)
1. The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.
Yang H; Wang K; Li B; Li S; Li Y; Yuan L
Front Oncol; 2021; 11():707041. PubMed ID: 34917497
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
3. Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study.
Hu M; Xu Q; Yang S; Han S; Zhu Y; Lin Q; Sun X; Liu H; Xu Y
Ann Transl Med; 2020 Oct; 8(20):1310. PubMed ID: 33209890
[TBL] [Abstract][Full Text] [Related]
4. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
[TBL] [Abstract][Full Text] [Related]
5. The high-risk features and effect of postoperative radiotherapy on survival for patients with surgically treated stage IIIA-N2 non-small cell lung cancer.
Zhu M; Li S; Yuan L; Liu S; Li J; Zhang D; Chen J; Jiang J; Xu Z
World J Surg Oncol; 2023 Aug; 21(1):238. PubMed ID: 37537652
[TBL] [Abstract][Full Text] [Related]
6. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
[No Abstract] [Full Text] [Related]
7. Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy.
Zheng C; Ye S; Liu W; Diao M; Li L
Front Oncol; 2023; 13():1276175. PubMed ID: 37901310
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era.
Li Q; Yu L; Yang P; Hu Q
Cancer Manag Res; 2021; 13():6799-6810. PubMed ID: 34512020
[TBL] [Abstract][Full Text] [Related]
9. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.
Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W
BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843
[TBL] [Abstract][Full Text] [Related]
10. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
Yan X; Li G
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
[TBL] [Abstract][Full Text] [Related]
11. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
12. Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy.
Chen D; Qin H; Deng G; Wang Q; Wang H; Liu X
Clin Transl Oncol; 2023 Jan; 25(1):226-235. PubMed ID: 36070068
[TBL] [Abstract][Full Text] [Related]
13. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy for patients with completely resected pathologic IIIA(N2) non-small-cell lung cancer: a retrospective analysis.
Zhu Y; Fu L; Jing W; Kong L; Yu J
Cancer Manag Res; 2019; 11():10901-10908. PubMed ID: 32021415
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
Cancer Manag Res; 2020; 12():1543-1567. PubMed ID: 32184659
[TBL] [Abstract][Full Text] [Related]
16. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of systemic inflammatory and nutritional indexes in locally advanced gastric cancer treated with adjuvant chemoradiotherapy after D2 dissection.
Wang SB; Chen JY; Xu C; Cao WG; Cai R; Cao L; Cai G
Front Oncol; 2022; 12():1040495. PubMed ID: 36387250
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
20. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
[No Abstract] [Full Text] [Related]
[Next] [New Search]
